Recombinant Human Mutant Tumor Necrosis Factor Alpha

• Cat.No.: TNF-25H
• Product Overview: The clinical use of the potent anti-tumor activity of TNF-alpha has been limited by the proinflammatory side effects including fever, dose-limiting hypotension, hepatotoxicity, intravascular thrombosis, and hemorrhage. Designing clinically applicable TNF-a mutants with low systemic toxicity has been an intense pharmacological interest. Human TNF-a, which binds to the murine TNF-R55 but not to the mouse TNF-R75, exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF-a, which binds to both murine TNF receptors. Based on these results, many TNF-a mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro, and exhibited lower systemic toxicity in vivo. Recombinant Human TNF-alpha Variant/Mutant compared with the wild-type, has an amino acid sequence deletion from a.a. 1-7, and the following a.a. substitutes Arg8, Lys9, Arg10 and Phe157 which is proven to have more activity and with less inflammatory side effect in vivo. Recombinant Human TNF-alpha Mutant produced in E. coli is a single, non-glycosylated, polypeptide chain containing 151 amino acids and having a molecular mass of 16,886 Dalton.

Specification

• Species: Human
• Source: E.coli
• Tag: Non
• Description: TNF is secreted by macrophages, monocytes, neutrophils, T-cells, NK-cells following their stimulation by bacterial LPS. Cells expressing CD4 secrete TNF-alpha while CD8 cells secrete little or no TNF-alpha. The synthesis of TNF-alpha is induced by many different stimuli including interferons, IL2, GM-CSF.
• Purity: >95% as determined by SEC-HPLC and SDS-PAGE .
• Formulation: Lyophilized from a 0.2 µm filtered solution in PBS.
• Specific Activity: The ED50 as determined by the cytolysis of murine L929 cells in the presence of Actinomycin D is less than 0.01 ng/ml, corresponding to a Specific Activity of 1.0 x 10⁸IU/mg.
• Endotoxin: Less than 0.01ng/µg (0.01IEU/µg) determined by LAL test.
• Reconstitution: It is recommended to reconstitute the lyophilized TNF-alpha Mutant in sterile 18MΩ-cm H₂O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.
• Storagee: Lyophilized samples are stable for up to twelve months from date of receipt at -20°C to -70°C. Aliquot to avoid repeated freeze-thaw cycles.

Gene Information

• Gene Name: TNF
• Synonyms: tumor necrosis factor (TNF superfamily, member 2); DIF; TNFA; TNFSF2; TNF-alpha; Cachectin; OTTHUMP00000037669; TNF-a; APC1 protein; TNF superfamily, member 2; TNF, macrophage-derived; TNF, monocyte-derived; Tumor necrosis factor ligand superfamily member 2; Tumor necrosis factor precursor; tumor necrosis factor; tumor necrosis factor (cachectin); tumor necrosis factor alpha; tumor necrosis factor, alpha (cachectin); TNF
• Gene ID: 7124
• mRNA Refseq: NM_000594.2
• Protein Refseq: NP_000585.2
• MIM: 191160
• UniProt ID: P01375
• Chromosome Location: 6p21.3
• Function: Cytokine activity, Identical protein binding, Tumor necrosis factor receptor binding